EE147 The Cost-Effectiveness of Olaparib Compared to Niraparib in the Treatment of Recurrent Ovarian Cancer Caused By BRCA1 and BRCA2 Gene Mutation from a US Healthcare Payer Perspective.
Year: 2022
Type: conference-abstract
Source: Value in Health
Authors: K Alkhuzam, D Guan, R Aroza, S Abuloha, H Shao
Institution: University of Florida
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4283526161